Just days after announcing a $150 million gene therapy deal with Cell Genesys Inc. (see BioCentury Extra Oct. 11), Hoechst Marion Roussel announced two three-year genomics research agreements - potentially worth nearly $50 million - with Incyte Pharmaceuticals Inc. and Lynx Therapeutics Inc.

"These agreements will put us in a better position to pursue avenues of research that will complement our traditional areas of drug research," said HMR CEO Charles Rouse. Indicating that more deals may be in